Opportunity Information: Apply for PAR 22 071
Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) is a National Institutes of Health funding opportunity (NCI/NIH; CFDA 93.394) aimed at pushing promising nanotechnology-based cancer tools beyond early discovery and into robust, advanced preclinical development. The core purpose is to support translational preclinical research that matures experimental nanomedicines, including nanoparticle and nanodevice platforms, when there is clear evidence that the intervention could improve cancer care because of the way the nano-structure is engineered and/or because of the therapeutic or diagnostic payload it carries and delivers. In practical terms, the program is looking for projects that move a nanotechnology cancer diagnostic or therapeutic closer to a development-ready state, with the kind of data package and technical readiness that would position it to transition into NCI translational pipelines such as the NCI Experimental Therapeutics (NExT) program or related NCI development programs.
This FOA uses the R01 grant mechanism and explicitly does not allow clinical trials, which signals that the expected work is preclinical rather than human-subject interventional research. The emphasis is on the stage of development where concepts should already be more than speculative: applicants are generally expected to have a credible lead candidate or platform, plus a plan to address key translational gaps that commonly block progress (for example, reproducible fabrication and characterization, performance in relevant models, safety or tolerability profiling appropriate for preclinical work, biodistribution and targeting behavior, dose and schedule exploration, proof-of-concept efficacy, and other studies that build confidence in moving toward an IND-enabling or programmatic handoff stage). The program description centers on “maturing” these interventions, meaning the work should reduce technical and biological uncertainty and produce decision-quality evidence about feasibility, potential benefit, and readiness for the next translational step.
The interventions of interest are nanotechnology-based cancer diagnostics and therapeutics, broadly conceived, as long as the nanoparticle or nanodevice design is integral to the claimed advantage. That includes approaches where the nano-scale architecture improves delivery, targeting, stability, controlled release, imaging contrast, multimodal functionality, or combinatorial therapeutic action compared with conventional formulations. A key idea running through the FOA is that the improved performance should be tied to the nanotechnology itself, whether through structural features (size, surface chemistry, shape, material composition, functionalization, device design) and/or through the specific cargo being carried (drug, biologic, nucleic acid, imaging agent, radiosensitizer, or other diagnostic/therapeutic payload). The translational intent also implies attention to how the intervention could realistically be advanced through development, including considerations that often matter later such as manufacturability, scalability, and quality control, even if the award remains preclinical.
Eligibility is broad across U.S.-based organizations and includes many types of government, academic, nonprofit, and commercial entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (when not institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. At the same time, it draws clear boundaries for non-U.S. involvement: non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined under the NIH Grants Policy Statement, are allowed, meaning a U.S.-based applicant can include certain well-justified foreign collaborations or elements within NIH policy limits.
Administratively, the opportunity is listed as PAR-22-071, categorized as discretionary funding, and uses the grant funding instrument. The activity category is listed under education and health, reflecting NIH’s broader classification system. The original closing date provided is 2024-11-17. The source data lists an award ceiling of 475,000 (as provided in the record), which should be interpreted in the context of NIH budget rules and the specific FOA instructions applicants must follow for allowable costs and requested budgets. The opportunity was created on 2021-11-23, indicating it has been available for multiple cycles and may have standard NIH due dates or reissues, so applicants typically need to confirm the current submission windows, budget guidance, and any FOA updates in the full announcement on NIH systems.
Overall, TTNCI is designed for teams who already have a compelling nanotechnology cancer intervention and now need support for the rigorous, translational preclinical work that de-risks the approach and makes it realistic for downstream NCI development pathways. The program is essentially a bridge between innovative nano-enabled cancer concepts and later-stage translational programs, with the clear expectation that funded projects will generate strong, development-oriented evidence rather than exploratory early discovery or human clinical testing.Apply for PAR 22 071
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2021-11-23.
- Applicants must submit their applications by 2024-11-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $475,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Toward Translation of Nanotechnology Cancer Interventions (TTNCI) funding opportunity?
TTNCI is a National Institutes of Health (NIH) / National Cancer Institute (NCI) funding opportunity focused on moving promising nanotechnology-based cancer diagnostics and therapeutics beyond early discovery into robust, advanced preclinical development. It supports translational preclinical research designed to mature a nanotechnology cancer intervention into a more development-ready state.
What is the official program name and FOA number?
The opportunity is titled Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed). The FOA number is PAR-22-071.
Which agency is offering this opportunity?
This is an NIH funding opportunity administered through the National Cancer Institute (NCI/NIH).
What funding mechanism is used?
This FOA uses the R01 grant mechanism and is offered as a grant funding instrument.
Are clinical trials allowed under this FOA?
No. The FOA explicitly states Clinical Trial Not Allowed, meaning the supported work is expected to be preclinical rather than human-subject interventional research.
What is the main purpose of TTNCI?
The core goal is to support translational preclinical studies that mature experimental nanomedicines (including nanoparticle and nanodevice platforms) when there is clear evidence the intervention could improve cancer care due to (1) how the nanostructure is engineered and/or (2) the therapeutic or diagnostic payload it carries and delivers.
What stage of research is TTNCI aimed at?
TTNCI is aimed at the stage where the concept is more than speculative. Projects should generally have a credible lead candidate or platform and focus on addressing key translational gaps to reduce technical and biological uncertainty and generate decision-quality evidence for the next step in development.
What types of projects are a good fit for TTNCI?
Projects that move a nanotechnology-based cancer diagnostic or therapeutic closer to a development-ready state by producing a stronger translational data package. The FOA emphasizes work that helps position a project for downstream transition into NCI translational pipelines such as the NCI Experimental Therapeutics (NExT) program or related NCI development programs.
What kinds of interventions are considered responsive?
The FOA is interested in nanotechnology-based cancer diagnostics and therapeutics broadly, as long as the nanotechnology (nanoparticle or nanodevice design) is integral to the claimed advantage and not incidental.
How should applicants justify that nanotechnology is providing the benefit?
The improved performance should be tied to the nanotechnology itself, such as through structural features (for example, size, surface chemistry, shape, material composition, functionalization, or device design) and/or through the payload being carried and delivered (such as drugs, biologics, nucleic acids, imaging agents, radiosensitizers, or other diagnostic/therapeutic cargo).
What kinds of advantages does the FOA associate with nano-engineered interventions?
The FOA highlights advantages that can come from nano-scale architecture, including improved delivery, targeting, stability, controlled release, imaging contrast, multimodal functionality, or combinatorial therapeutic action compared with conventional formulations.
What types of preclinical activities does TTNCI emphasize?
The FOA emphasizes translational preclinical activities that commonly block progress, including (as examples mentioned in the description): reproducible fabrication and characterization; performance in relevant models; preclinical safety or tolerability profiling; biodistribution and targeting behavior; dose and schedule exploration; proof-of-concept efficacy; and other studies that build confidence for a later IND-enabling stage or a programmatic handoff.
Does the FOA require attention to manufacturability and scalability?
Yes, the translational intent implies attention to real-world development considerations such as manufacturability, scalability, and quality control, even though the award supports preclinical work.
Is this opportunity meant for early discovery research?
Not primarily. The FOA emphasizes “maturing” interventions and generating development-oriented evidence rather than exploratory early discovery.
What is meant by “maturing” a nanotechnology intervention in this FOA?
In this context, “maturing” means conducting rigorous preclinical translational work that reduces uncertainty, strengthens reproducibility, and produces decision-quality evidence about feasibility, potential benefit, and readiness for the next translational step.
What is CFDA 93.394?
The opportunity is associated with CFDA 93.394, as listed in the provided information for this NIH/NCI funding area.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and includes government, academic, nonprofit, and commercial entities. Examples listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofits (with or without 501(c)(3) status, when not institutions of higher education); for-profit organizations (other than small businesses); and small businesses.
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA explicitly highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
Can U.S. territories apply?
Yes. The FOA includes U.S. territories or possessions among the explicitly highlighted eligible applicant categories.
Are federal agencies eligible to apply?
Yes. The FOA lists eligible federal agencies among the highlighted eligible applicant categories.
Can non-U.S. (foreign) institutions apply as the main applicant?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply.
Are foreign components allowed at all?
Yes. The FOA states that foreign components, as defined under the NIH Grants Policy Statement, are allowed. This means a U.S.-based applicant may include certain well-justified foreign collaborations or elements within NIH policy limits.
What is the opportunity type and how is it categorized?
The opportunity is listed as discretionary funding and uses a grant funding instrument. The activity category is listed under education and health in the provided classification.
What is the listed application closing date?
The original closing date provided is 2024-11-17. Applicants are expected to confirm current submission windows and any updates in the full announcement on NIH systems.
When was this opportunity created?
The source information indicates the opportunity was created on 2021-11-23.
Is this a one-time opportunity or does it run across multiple cycles?
The provided information indicates it has been available for multiple cycles (based on the 2021 creation date) and may follow standard NIH due dates or be reissued. Applicants should verify the current submission windows and any FOA updates in the full announcement.
What is the listed award ceiling?
The source data lists an award ceiling of 475,000. This should be interpreted in the context of NIH budget rules and the specific FOA instructions on allowable costs and requested budgets.
What is the expected outcome of a successful TTNCI project?
A successful project is expected to produce a robust, development-oriented preclinical package that reduces key risks and positions the intervention for transition into NCI translational pipelines (such as NExT) or related development programs.
Does TTNCI focus on diagnostics, therapeutics, or both?
Both. The FOA supports nanotechnology-based cancer diagnostics and therapeutics, as long as the nano-engineering is central to the proposed advantage.
Does the FOA restrict the type of payloads or cargos used?
The description is broad and includes payload examples such as drugs, biologics, nucleic acids, imaging agents, radiosensitizers, and other diagnostic/therapeutic payloads, provided the nano-enabled design is integral to performance.
How does TTNCI relate to IND-enabling work?
The FOA emphasizes generating data that builds confidence in moving toward an IND-enabling stage or a programmatic handoff, while remaining within a preclinical scope.
Browse more opportunities from the same category: Education, Health
Next opportunity: Cooperative Agreement for CESU-affiliated Partner with Piedmont-South Atlantic Coast Cooperative Ecosystem Studies Unit
Previous opportunity: Court Monitoring Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 071
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 071) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Apply for RFA CA 22 001 Funding Number: RFA CA 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 22 002 Funding Number: RFA CA 22 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed) Apply for PAR 22 031 Funding Number: PAR 22 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional) Apply for PAR 21 358 Funding Number: PAR 21 358 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed) Apply for RFA DA 22 044 Funding Number: RFA DA 22 044 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed) Apply for RFA DA 22 045 Funding Number: RFA DA 22 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Pilot and Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional) Apply for RFA DA 22 048 Funding Number: RFA DA 22 048 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional) Apply for RFA DA 22 047 Funding Number: RFA DA 22 047 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional) Apply for RFA DA 22 043 Funding Number: RFA DA 22 043 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional) Apply for RFA DA 22 046 Funding Number: RFA DA 22 046 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional) Apply for RFA DA 22 042 Funding Number: RFA DA 22 042 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional) Apply for RFA DA 22 034 Funding Number: RFA DA 22 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional) Apply for RFA DA 22 051 Funding Number: RFA DA 22 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional) Apply for RFA DA 22 049 Funding Number: RFA DA 22 049 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional) Apply for RFA MH 22 170 Funding Number: RFA MH 22 170 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) Apply for RFA CA 22 008 Funding Number: RFA CA 22 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) Apply for RFA CA 22 007 Funding Number: RFA CA 22 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Apply for RFA CA 22 010 Funding Number: RFA CA 22 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 22 006 Funding Number: RFA CA 22 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 22 005 Funding Number: RFA CA 22 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 071", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.